Abstract: The invention discloses compositions and methods comprising enriched Bisdemethoxycurcumin (BDMC) present not less than 20% w/w for use in inhibiting Receptor for Advanced Glycation End-Products (RAGE) expression in a subject with chronic-inflammatory condition. The composition further comprises ?-amyrin palmitate (BAP). The invention also includes disclose the use of the above composition in the management of chronic inflammatory condition in a subject.

Abstract: The invention discloses a composition comprising not less than 20% w/w bisdemethoxycurcumin for regeneration of alveolar cells damaged in emphysematous conditions and for the therapeutic management of chronic obstructive pulmonary disease and acute respiratory distress syndrome. The composition further comprises 10-35% w/w demethoxycurcumin and 10-45% w/w curcumin. The composition is very suitable for treating COPD and ARDS due to viral infections, specifically COVID 19 and for improving lung function during prognosis.

Abstract: The present invention discloses a method for therapeutic management of pulmonary fibrosis in mammals using a composition comprising iso-garcinol or octahydrocurcumin or a combination of iso-garcinol and octahydrocurcumin. The composition is very suitable for treating pulmonary fibrosis due to viral infections, specifically COVID 19 and for improving lung function during prognosis.

Abstract: The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of metabolic syndrome in mammals.

Abstract: The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of interstitial lung disease or lung fibrosis.

Abstract: The present invention discloses the potential of probiotic bacteria Bacillus coagulans individually or in combination with multi-enzyme complex for reducing gluten content in foods rich in gluten and for the increased utilization of gluten. The invention further discloses a method for the management of gluten intolerance using composition comprising Bacillus coagulans and multi-enzyme complex in mammals.

Abstract: The present invention discloses a method for therapeutic management of atrophic gastritis and colitis using a composition comprising Bacillus coagulans MTCC 5856 individually or in combination with anthocyanins. The invention further discloses a method for preventing neoplastic transformation of mucosal cells in gastro-intestinal tract and improving gut barrier function in mammals using a composition comprising Bacillus coagulans MTCC 5856 individually or in combination with anthocyanins.

Abstract: The present invention discloses a method for protecting mammalian skin against the harmful effects of UV radiation and environmental pollutants, using one or plant actives selected from group comprising a composition comprising not less than 10% w/w oroxylin A, not less than 10% w/w baicalein and not less than 2% w/w chrysin; 95% w/w oxyresveratrol; 95% w/w tetrahydrocurcumin; 90% w/w pterostilbene and a composition comprising at least 10% w/w ?-glucogallin and at least 10% w/w total mucic acid gallates. The invention also discloses a method for cleansing and rejuvenating mammalian skin, exposed to environmental pollutants and UV radiation using the aforesaid plant actives.

Abstract: The present invention discloses a novel fructophilic lactic acid producing bacteria Bacillus coagulans strain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria.

Abstract: The present invention discloses a novel endophytic fungi, Ovatospora brasiliensis MTCC 25236 for the bioconversion of curcuminoids to Calebin-A and a method for its isolation from the rhizomes of Curcuma sp. The invention also discloses a method for the bioconversion of curcuminoids to Calebin-A using an endophytic fungi Ovatospora brasiliensis MTCC 25236 and bacterial species, Acinetobacter johnsonii and Pseudomonas putida.

Abstract: The present invention discloses a stable probiotic composition comprising Bacillus coagulans individually and/or in combination with multi-enzyme complex for the utilization of lactose and therapeutic management of lactose intolerance. It also discloses a method for the management of lactose intolerance using composition comprising Bacillus coagulans individually and/or in combination with multi-enzyme complex.

Abstract: The present invention discloses a composition comprising not less than 10% w/w of oroxylin A, not less than 10% w/w of baicalein and not less than 2% w/w of chrysin for use reducing the incidence of seizures and in the management of neurotoxicity induced by seizures.

Abstract: The present invention discloses a composition comprising not less than 10% w/w of oroxylin A, not less than 10% w/w of baicalein and not less than 2% w/w of chrysin for use in the therapeutic management of hypertriglyceridemia, associated with chemotherapy and hyperglycemia.